These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 38132297)

  • 1. Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
    Gabbia D; De Martin S
    Biology (Basel); 2023 Nov; 12(12):. PubMed ID: 38132297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breaking the barriers: the role of gut homeostasis in Metabolic-Associated Steatotic Liver Disease (MASLD).
    Benedé-Ubieto R; Cubero FJ; Nevzorova YA
    Gut Microbes; 2024; 16(1):2331460. PubMed ID: 38512763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbiota modulation by dietary oat beta-glucan prevents steatotic liver disease progression.
    Jaeger JW; Brandt A; Gui W; Yergaliyev T; Hernández-Arriaga A; Muthu MM; Edlund K; Elashy A; Molinaro A; Möckel D; Sarges J; Halibasic E; Trauner M; Kahles F; Rolle-Kampczyk U; Hengstler J; Schneider CV; Lammers T; Marschall HU; von Bergen M; Camarinha-Silva A; Bergheim I; Trautwein C; Schneider KM
    JHEP Rep; 2024 Mar; 6(3):100987. PubMed ID: 38328439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAD metabolic therapy in metabolic dysfunction-associated steatotic liver disease: Possible roles of gut microbiota.
    Lu X; Yang R; Chen Y; Chen D
    iScience; 2024 Mar; 27(3):109174. PubMed ID: 38405608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of gut barrier integrity and host-microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus.
    Forlano R; Martinez-Gili L; Takis P; Miguens-Blanco J; Liu T; Triantafyllou E; Skinner C; Loomba R; Thursz M; Marchesi JR; Mullish BH; Manousou P
    Gut Microbes; 2024; 16(1):2304157. PubMed ID: 38235661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications.
    Yu L; Gao F; Li Y; Su D; Han L; Li Y; Zhang X; Feng Z
    Biomed Pharmacother; 2024 Jun; 175():116724. PubMed ID: 38761424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation.
    Min BH; Devi S; Kwon GH; Gupta H; Jeong JJ; Sharma SP; Won SM; Oh KK; Yoon SJ; Park HJ; Eom JA; Jeong MK; Hyun JY; Stalin N; Park TS; Choi J; Lee DY; Han SH; Kim DJ; Suk KT
    Gut Microbes; 2024; 16(1):2307568. PubMed ID: 38299316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut microbial metabolites in MASLD: Implications of mitochondrial dysfunction in the pathogenesis and treatment.
    Zhang R; Yan Z; Zhong H; Luo R; Liu W; Xiong S; Liu Q; Liu M
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38967596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options.
    Vallianou NG; Kounatidis D; Psallida S; Vythoulkas-Biotis N; Adamou A; Zachariadou T; Kargioti S; Karampela I; Dalamaga M
    Metabolites; 2024 Jun; 14(7):. PubMed ID: 39057689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.
    Park IG; Yoon SJ; Won SM; Oh KK; Hyun JY; Suk KT; Lee U
    Sci Rep; 2024 Jul; 14(1):16122. PubMed ID: 38997279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical improvement effect of regulating gut microbiota on metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis of randomized controlled trials.
    Wu J; Chen X; Qian J; Li G
    Clin Res Hepatol Gastroenterol; 2024 Jun; 48(7):102397. PubMed ID: 38879003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α.
    Hai S; Li X; Xie E; Wu W; Gao Q; Yu B; Hu J; Xu F; Zheng X; Zhang BH; Wu D; Yan W; Ning Q; Wang X
    Hepatology; 2024 Jul; ():. PubMed ID: 38985971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of Gut Microbiota Composition in the Progression of Liver Damage in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Zazueta A; Valenzuela-Pérez L; Ortiz-López N; Pinto-León A; Torres V; Guiñez D; Aliaga N; Merino P; Sandoval A; Covarrubias N; Pérez de Arce E; Cattaneo M; Urzúa A; Roblero JP; Poniachik J; Gotteland M; Magne F; Beltrán CJ
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Backer S; Khanna D
    Cureus; 2023 Sep; 15(9):e45231. PubMed ID: 37842470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease.
    Sawada K; Chung H; Softic S; Moreno-Fernandez ME; Divanovic S
    Cell Metab; 2023 Nov; 35(11):1852-1871. PubMed ID: 37939656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma.
    Ha S; Wong VW; Zhang X; Yu J
    Gut; 2024 Jun; ():. PubMed ID: 38950910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Microbiota-Related Co-Metabolites in MASLD Progression: A Narrative Review.
    Martin-Grau M; Monleón D
    Curr Issues Mol Biol; 2024 Jun; 46(7):6377-6389. PubMed ID: 39057023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.